News & Press

Moderna Positive Phase 3 Results of mRNA-1273 Vaccine Candidate

November 16, 2020
News > CordenPharma Congratulates Moderna on positive Phase 3 results of mRNA-1273 COVID-19 vaccine.

CordenPharma Congratulates Moderna on the positive Phase 3 COVE study results of their mRNA-1273 COVID-19 vaccine candidate, which has met its primary efficacy endpoint in their first interim analysis.


CordenPharma congratulates Moderna on the November 16 Press Release announcement of positive Phase 3 COVE study results of their mRNA-1273 COVID-19 vaccine candidate, which has met its primary efficacy endpoint in their first interim analysis. CordenPharma is proud to continue supporting their vaccine efforts to with our specialized lipid manufacturing.

CordenPharma Congratulates Moderna on positive mRNA-1273 COVID-19 vaccine candidate Phase 3 results

CordenPharma congratulates Moderna on the positive Phase 3 COVE study results of their mRNA-1273 COVID-19 vaccine candidate, which has met its primary efficacy endpoint in their first interim analysis.